Halozyme Therapeutics, Inc. (HALO) — SEC Filings
Halozyme Therapeutics, Inc. (HALO) — 32 SEC filings. Latest: 8-K (Dec 9, 2025). Includes 16 8-K, 6 10-Q, 5 SC 13G/A.
View Halozyme Therapeutics, Inc. on SEC EDGAR
Overview
Halozyme Therapeutics, Inc. (HALO) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 9, 2025: On December 4, 2025, Halozyme Therapeutics, Inc. announced changes in its executive team and board of directors. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for key executives. Specific names and financia
Sentiment Summary
Across 32 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 29 neutral. The dominant filing sentiment for Halozyme Therapeutics, Inc. is neutral.
Filing Type Overview
Halozyme Therapeutics, Inc. (HALO) has filed 16 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 5 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (32)
Risk Profile
Risk Assessment: Of HALO's 23 recent filings, 0 were flagged as high-risk, 10 as medium-risk, and 13 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $944.844M |
| Net Income | $458.480M |
| EPS | $3.68 |
| Debt-to-Equity | 3.41 |
| Cash Position | $419.665M |
| Operating Margin | 59.5% |
| Total Assets | $2,221.232M |
| Total Debt | $1,510.757M |
Industry Context
The biopharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Halozyme operate in a competitive landscape where innovation in drug delivery technologies and strategic partnerships are crucial for market differentiation and revenue generation. The trend towards more convenient and effective drug administration methods, such as subcutaneous injections, is a key driver for technologies like ENHANZE.
Top Tags
8-K (4) · management-change (3) · executive-compensation (3) · disclosure (3) · filing (3) · compensation (3) · institutional-ownership (3) · amendment (3) · material-agreement (2) · 10-Q (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Total Revenues | $944.844M | Increased by 31.7% for the nine months ended September 30, 2025, compared to $717.316 million in 2024. |
| Royalties | $609.869M | Increased by 52.2% for the nine months ended September 30, 2025, compared to $400.572 million in 2024. |
| Net Income | $458.480M | Increased by 49.3% for the nine months ended September 30, 2025, compared to $307.079 million in 2024. |
| Diluted EPS | $3.68 | Increased from $2.37 for the nine months ended September 30, 2024. |
| Cash and Cash Equivalents | $419.665M | Increased significantly from $115.850 million at December 31, 2024. |
| Net Cash Provided by Operating Activities | $432.529M | For the nine months ended September 30, 2025, up from $300.597 million in 2024. |
| Repurchase of Common Stock | $342.372M | For the nine months ended September 30, 2025, reducing outstanding shares. |
| Shares Outstanding (in thousands) | 117,523 | As of September 30, 2025, down from 123,138 thousand at December 31, 2024. |
| Current Portion of Long-Term Debt | $710.685M | Increased from $0 at December 31, 2024, indicating reclassification. |
| Long-Term Debt, net | $800.072M | Decreased from $1,505.798 million at December 31, 2024, due to reclassification. |
| Reporting Period | 2025 Q1 | First quarter of 2025 financial data |
| Prior Year Q1 Period | 2024-01-01 to 2024-03-31 | Comparison period for Q1 2024 |
| Current Year Q1 Period | 2025-01-01 to 2025-03-31 | Reporting period for Q1 2025 |
| Fiscal Year | 2024 | Reporting period for the 10-K filing. |
| Fiscal Year End | 1231 | Indicates the end date of the fiscal year reported. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Halozyme Therapeutics, Inc. (HALO)?
Halozyme Therapeutics, Inc. has 32 recent SEC filings from Jan 2024 to Dec 2025, including 16 8-K, 6 10-Q, 5 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of HALO filings?
Across 32 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 29 neutral. The dominant sentiment is neutral.
Where can I find Halozyme Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Halozyme Therapeutics, Inc. (HALO) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Halozyme Therapeutics, Inc.?
Key financial highlights from Halozyme Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for HALO?
The investment thesis for HALO includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Halozyme Therapeutics, Inc.?
Executive information for Halozyme Therapeutics, Inc. is extracted from SEC filings as they are enriched with AI analysis.
What are the main risk factors for Halozyme Therapeutics, Inc. stock?
Of HALO's 23 assessed filings, 0 were flagged high-risk, 10 medium-risk, and 13 low-risk.
What are recent predictions and forward guidance from Halozyme Therapeutics, Inc.?
Forward guidance and predictions for Halozyme Therapeutics, Inc. are extracted from SEC filings as they are enriched.